Fig. 1: Study design and treatment outcomes.
From: Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
a Immune profiling was performed on blood and bone marrow collected from 23 patients with multiple myeloma receiving lenalidomide as maintenance therapy (created with BioRender.com). b Swimmer plot showing duration and depth of response to lenalidomide in relation to the sample collection time points and immune assays performed. c Kaplan–Meier survival analysis of progression-free survival from the start of the initiation of maintenance therapy for all patients and d stratified according to the minimal residual disease (MRD) negative status. PR partial response, VGPR very good partial response, CR complete response, TCR T-cell receptor, BMMC bone marrow mononuclear cells, PBMC peripheral blood mononuclear cells. Source data are provided as a Supplementary Data file.
